MRSA (methicillin-resistant staphylococcus aureus)

MRSA is presently a pathogen of global health concern. . They are S. aureus strains that are resistant to oxacillin, nafcillin and methicillin. They can also be resistant to all ß-lactam agents.  It can cause a variety of problems ranging from skin infections and sepsis to pneumonia and various types of bloodstream infections. The infections occur commonly among people in hospitals and healthcare facilities such as nursing homes, diagnostic centres and dialysis centres, who have less stable immune systems. The current arsenal of antibiotics available for the treatment of MRSA includes a topical agent, a limited number of oral agents.

 

  • Community-acquired MRSA (CA-MRSA)
  • Healthcare-associated MRSA (HA-MRSA)
  • Virulence Associated Factors of CA-MRSA
  • Antibiotic resistance
  • Recurrent MRSA Infections
  • Oral and intravenous agents
  • Topical agents
  • Vancomycin, Clindamycin and linezolid
  • Pneumonia (HAP/VAP)
  • Chronic osteomyelitis (COM)
  • Skin and soft tissue infections

Related Conference of MRSA (methicillin-resistant staphylococcus aureus)

August 19-20, 2020

European Summit on HIV, STD and STIs

Milan, Italy
September 28-29, 2020

13th Global Infections Conference

Singapore
October 5-6, 2020

12th Euro-Global Conference on Infectious Diseases

Vienna, Austria
November 05-06, 2020

9th Asia Pacific STD and Infectious Diseases Congress

Tokyo, Japan
February 15-16, 2021

8th International Congress on Infectious Diseases

London, UK
February 22-23, 2021

4th Global Experts Meeting on Infectious Diseases

Singapore City, Singapore

MRSA (methicillin-resistant staphylococcus aureus) Conference Speakers

Recommended Sessions

Related Journals

Are you interested in